Immunotherapy-induced Addison’s disease: a rare, persistent and potentially lethal side-effect
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The plausible mechanisms underlying immune checkpoint inhibitor-induced adrenal insufficiency are adrenal hypofunction (primary adrenal insufficiency) or pituitary ACTH deficiency (secondary adrenal insufficiency).
“The plausible mechanisms underlying the development of AI by ICIs are adrenal hypofunction (primary AI) or pituitary ACTH deficiency (secondary AI).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [32]
Primary adrenal insufficiency is related to immune destruction of the adrenal glands consequent to hyperstimulation of the immune system due to the mechanism of action of immune checkpoint inhibitors.
“Primary AI is related to an immune destruction of the adrenal glands consequent to a hyperstimulation of the immune system due to ICIs mechanism of action.”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [32]
Primary adrenal insufficiency has been linked to antiadrenal antibodies and adrenal gland atrophy.
“It has been linked to antiadrenal antibodies (32, 33), while atrophy of the glands has been reported as well (33).”
From The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System (2022) · cites this paper as [32]
Cites
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · see citing works
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Trainer, H., Hulse, P., Higham, C. E., Trainer, P., & Lorigan, P. (2016) · Endocrinology, Diabetes & Metabolism Case Reports · doi:10.1530/edm-16-0108 · Cited by 117 · see citing works
Ipilimumab-induced autoimmune adrenalitis
Min, L., & Ibrahim, N. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70031-7 · Cited by 112 · see citing works
Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma
Paepegaey, A.-C., Lheure, C., Ratour, C., Lethielleux, G., Clerc, J., Bertherat, J., Kramkimel, N., & Groussin, L. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00170 · Cited by 102 · see citing works
Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT
Bacanovic, S., Burger, I. A., Stolzmann, P., Hafner, J., & Huellner, M. W. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000887 · Cited by 82 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C., Lupi, I., Paschou, S. Α., Tóth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 214 · see citing works
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140 · see citing works
Self-citationEpidemiology, pathogenesis, and diagnosis of Addison’s disease in adults
Betterle, C., Presotto, F., & Furmaniak, J. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01079-6 · Cited by 139 · see citing works
Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis
Grouthier, V., Lebrun-Vignes, B., Moey, M., Johnson, D. B., Moslehi, J. J., Salem, J.-E., & Bachelot, A. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0555 · Cited by 126 · see citing works
Biointerface engineering nanoplatforms for cancer-targeted drug delivery
Zhang, H., Dong, S., Li, Z., Feng, X., Xu, W., Tulinao, C. M. S., Jiang, Y., & Ding, J. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.11.004 · Cited by 72 · see citing works
Iwama, S., Kobayashi, T., & Arima, H. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01077-6 · Cited by 46 · see citing works
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy
Atkinson, M. A., & Lansdown, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101635 · Cited by 32 · see citing works
Shi, Y., Shen, M., Zheng, X., & Yang, T. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.09.016 · Cited by 29 · see citing works
Shi, Y., Shen, M., Zheng, X., Chen, Y., Zhao, R., Gu, Y., & Yang, T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa553 · Cited by 25 · see citing works
Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non–Small Cell Lung Cancer
Shroff, G. S., Strange, C. D., Ahuja, J., Altan, M., Sheshadri, A., Ünlü, E., Truong, M. T., & Vlahos, I. (2022) · Radiographics · doi:10.1148/rg.220108 · Cited by 22 · see citing works
Sick sinus syndrome associated with anti-programmed cell death-1
Hsu, C., Su, Y., & Chen, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0388-9 · Cited by 21 · see citing works
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Profili, N. I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., & Delitala, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155161 · Cited by 18 · see citing works
Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac359 · Cited by 17 · see citing works
Deligiorgi, M. V., & Trafalis, D. T. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107050 · Cited by 17 · see citing works
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
Mytareli, C., Ziogas, D. C., Karampela, A., Papalexis, P., Siampanopoulou, V., Lafioniatis, A., Benopoulou, Ο., Gogas, H. J., & Angelousi, A. G. (2023) · Cancers · doi:10.3390/cancers15072016 · Cited by 19 · see citing works
Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17 · see citing works
Expert opinions on adrenal complications in immunotherapy
Haissaguerre, M., Hescot, S., Bertherat, J. Y., & Chabre, O. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.002 · Cited by 16 · see citing works
Self-citationEndocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 15 · see citing works
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13 · see citing works
Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α
Dasgupta, A., Tsay, E., Federman, N. C., Lechner, M. G., & Su, M. A. (2022) · PEDIATRICS · doi:10.1542/peds.2021-053363 · Cited by 13 · see citing works
Pan, Q., & Li, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366335 · Cited by 9 · see citing works
Pituitary and adrenal disorders induced by immune checkpoint inhibitors
Albarel, F., Brue, T. C., & Castinetti, F. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.014 · Cited by 7 · see citing works
Post-immunotherapy imaging in lung cancer
Shroff, G. S., Strange, C. D., Altan, M., Carter, B. W., Ahuja, J., Godoy, M. C. B., Truong, M. T., & Vlahos, I. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.05.003 · Cited by 7 · see citing works
Autoimmune Primary Adrenal Insufficiency: Understanding the Past, Present, and Future
Surani, A., & Carroll, T. B. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.008 · Cited by 4 · see citing works
Yamabayashi, E., Obata, Y., Kozawa, J., Nishizawa, H., & Shimomura, I. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf123 · Cited by 2 · see citing works
Editorial: From Chronic Inflammation to Cancer: How Far Can Immunotherapy Go?
Li, X., Teng, L., & Yang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.838917 · Cited by 2 · see citing works
Wémeau, J.-L., BERTAGNA, X. Y., & Boîtard, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30188-8 · Cited by 1 · see citing works
Green, H. E., & Nieva, J. J. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001806 · Cited by 1 · see citing works
Endocrinopathies Associated With Immune Checkpoint Inhibitors
Girotra, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00024-7
(2018) · Reactions Weekly · doi:10.1007/s40278-018-48365-6
Colombo, C. M., Leo, S. D., Campisi, I., Palesandro, E., Turco, F., Buttigliero, C., Fugazzola, L., & Tucci, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104627
- Authors
- Hescot, S., Haissaguerre, M., Pautier, P., Kuhn, E., Schlumberger, M., & Berdelou, A.
- Affiliations
- Institut Gustave Roussy (FR)
- Bicêtre Hospital (FR)
- Corresponding author
- Hescot, S.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 97
- Pages
- 57-58
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2800663506
- Cited by
- 31
- References
- 5
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- Addison's disease, adrenal insufficiency, pembrolizumab, immune checkpoint inhibitors, cancer immunotherapy, autoimmune adrenal insufficiency, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Addison Disease, Adult, Uterine Cervical Neoplasms, Female, Humans, Immunotherapy, Fatal Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
